Tirzepatide (Zepbound, Mounjaro) is a dual-agonist GLP-1 medication. It works like a GLP-1 agonist, but also targets a hormone called glucose-dependent insulinotropic polypeptide (GIP) to “help break down sugar and fat,” according to Chatham.

G whiz! The latest experimental GLP-1 from Eli Lilly isn’t just a diabetes drug — it also facilitates weight loss. Known as “triple-G,” injectable retatrutide levies a triple whammy on the GLP-1, GIP and glucagon hormones,

With a second oral GLP-1 for obesity now approved in the U.S., analysts have set to work parsing the blockbuster potential of Eli Lilly’s Foundayo in 2026, as well as the dynamics at play with Novo | As the battle for the weight-loss market expands to oral drugs,

Here’s how retatrutide works and how it differs from existing weight management medications.

From Zepbound to cancer care, insurance denials are up in 2026. Even with good insurance, consumers face steep bills for popular drugs.

Demand for these drugs is high, and analysts predict the market will reach nearly $100 billion by the end of the decade. And Lilly just this week won regulatory approval for Foundayo (orforglipron), its GLP-1 pill for weight loss -- this product could significantly add to growth.

Zepbound (tirzepatide) and Mounjaro (tirzepatide) are prescription drugs used to treat different conditions. Zepbound and Mounjaro are not available as generic drugs. The two drugs have some similarities and differences, such as side effects, uses, and ...

From Zepbound to cancer care, insurance denials are up in 2026. Even with good insurance, consumers face steep bills for popular drugs.